Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies Journal Article


Authors: Mughal, T. I.; Girnius, S.; Rosen, S. T.; Kumar, S.; Wiestner, A.; Abdel-Wahab, O.; Kiladjian, J. J.; Wilson, W. H.; Van Etten, R. A.
Article Title: Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies
Abstract: Over the past decade, there has been increasing biochemical evidence that the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is aberrantly activated in malignant cells from patients with a wide spectrum of cancers of the blood and immune systems. The emerging availability of small molecule inhibitors of JAK and other signaling molecules in the JAK/STAT pathway has allowed preclinical studies validating an important role of this pathway in the pathogenesis of many hematologic malignancies, and provided motivation for new strategies for treatment of these diseases. Here, a round-table panel of experts review the current preclinical and clinical landscape of the JAK/STAT pathway in acute lymphoid and myeloid leukemias, lymphomas and myeloma, and chronic myeloid neoplasms.
Keywords: tyrosine kinase jak2; acute lymphoblastic-leukemia; multiple-myeloma; b-cell lymphoma; acute myeloid-leukemia; factor-kappa-b; hematological malignancies; of-function mutations; jak2 v617f mutation; dna-binding activity; jak/stat pathway; jak inhibitors; myeloproliferative-disorders
Journal Title: Leukemia and Lymphoma
Volume: 55
Issue: 9
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2014-09-01
Start Page: 1968
End Page: 1979
Language: English
ACCESSION: WOS:000340460200005
DOI: 10.3109/10428194.2013.863307
PROVIDER: wos
PUBMED: 24206094
PMCID: PMC4344832
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors